This analysis examines Indraprastha Medical Corporation Ltd. (INDRAMEDCO) through the lens of its financial statements, valuation metrics, and institutional ownership patterns.
Indraprastha Medical Revenue Trend
Indraprastha Medical Corporation Ltd. clocked ₹1,379 Cr in revenue for FY2025, up 9.3% from FY2024.
The 10-year revenue CAGR of 6.8% reflects steady — if not spectacular — top-line expansion from ₹713 Cr to ₹1,379 Cr.
With a top line of ₹1,379 Cr, Indraprastha Medical Corporation Ltd. operates at a mid-sized scale within the healthcare sector.
Looking at the year-on-year numbers, Indraprastha Medical Corporation Ltd. has seen 4 years of unbroken revenue growth.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹1,379 Cr | +9.3% |
| FY2024 | ₹1,262 Cr | +13.8% |
| FY2023 | ₹1,109 Cr | +24.4% |
| FY2022 | ₹891 Cr | +45.3% |
| FY2021 | ₹613 Cr | — |
View Indraprastha Medical Corporation Ltd.'s full 10-year revenue trend with CAGR analysis →
Indraprastha Medical Profitability
Year-over-year, net profit grew 29.9% from ₹124 Cr to ₹161 Cr in FY2025 for Indraprastha Medical Corporation Ltd..
A stronger net margin of 11.7% in FY2025 (from 9.8%) points to better profitability per rupee of revenue.
On a per-share basis, diluted earnings were ₹17.56 in FY2025 versus ₹13.52 in FY2024.
Is Indraprastha Medical Undervalued
The P/E Ratio approach puts Indraprastha Medical Corporation Ltd.'s intrinsic value at ₹401, a 0.1% downside from the current market price.
Indraprastha Medical Corporation Ltd. shares are currently trading at ₹401.45.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹401 | 0.1% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Indraprastha Medical Corporation Ltd. with detailed assumptions →
Indraprastha Medical Shareholding Pattern
Promoter holding is steady at 51.0% — no buying or selling over the past 4 quarters.
FII ownership stands at 2.4%, down from the 2.7% recorded a year ago.
As of March 2026, DIIs own 0.9% of the company — down from 3.6% a year earlier.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 51.0% | 2.4% | 0.9% | 45.7% |
| Dec 2025 | 51.0% | 2.7% | 0.8% | 45.4% |
| Sep 2025 | 51.0% | 2.4% | 3.5% | 43.1% |
| Jun 2025 | 51.0% | 2.7% | 3.6% | 42.7% |
Track quarterly shareholding changes for Indraprastha Medical Corporation Ltd. →
Indraprastha Medical Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹8.52B, up 17.8% YoY from ₹7.23B.
Property, Plant & Equipment accounts for 38.6% of the total, ahead of Cash & ST Investments (37.8%) and Receivables (8.9%).
Capital structure: 70.1% equity, 3.8% debt, 26.1% operating liabilities. Over the year, debt is down 3.5% and equity is up 24.9%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 3.22B |
| Receivables | 754.50M |
| Inventories | 69.90M |
| Property, Plant & Equipment | 3.29B |
| Investments | 571.20M |
| Intangibles & Goodwill | 5.90M |
| Other Assets | 607.70M |
| Category | Value |
|---|---|
| Equity | 5.97B |
| Short-term Debt | 22.20M |
| Long-term Debt | 305.40M |
| Trade Payables | 1.23B |
| Other Liabilities | 996.40M |
Indraprastha Medical at a Glance
Pulling it all together, here's what the numbers say about Indraprastha Medical Corporation Ltd. (INDRAMEDCO) heading into the next fiscal year.
Revenue of ₹1,379 Cr in FY2025, up 9.3% year-over-year.
Long-term revenue has been compounding at 6.8% annually over 10 years.
The company is profitable, with a net margin of 11.7% and net income of ₹161 Cr.
The P/E Ratio model implies 0.1% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Indraprastha Medical Corporation Ltd..